## BMY: Bristol-Myers Squibb Company - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.9% below STRENGTH zone (3.0-6.0%); PEG 2.26 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($50.94)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Bristol-Myers Squibb (BMY) stock fell Friday — here’s what investors are watching next**
- Source: ts2.tech | 20260103T225836 | Somewhat-Bearish | Relevance: 100%
- Bristol-Myers Squibb (BMY) shares dropped 0.9% on Friday, closing at $53.46, despite the broader healthcare sector's positive performance. The drop occurred ahead of the company's presentation at J.P. Morgan's 44th Annual Healthcare Conference and in the context of a new Medicaid pricing agreement for its drug Eliquis. Investors are now looking forward to the conference presentation and the upcoming Q4 and full-year 2025 earnings report on February 5th for insights into 2026 expectations and the financial impact of the Eliquis agreement.

**2. Railway Pension Investments Ltd Purchases 40,300 Shares of Bristol Myers Squibb Company $BMY**
- Source: MarketBeat | 20260105T123008 | Somewhat-Bullish | Relevance: 100%
- Railway Pension Investments Ltd increased its stake in Bristol Myers Squibb (BMY) by 3.7% in Q3, purchasing an additional 40,300 shares, bringing its total holdings to 1,139,600 shares valued at approximately $51.4 million. The biopharmaceutical company recently exceeded its Q3 earnings and revenue estimates and raised its quarterly dividend to $0.63 per share, representing an annualized yield of 4.7%. Despite a consensus "Hold" rating from analysts, institutional investors now own about 76.4% of the stock.

**3. Motley Fool: Fat dividend and a chance for growth**
- Source: The Spokesman-Review | 20260104T140805 | Bullish | Relevance: 100%
- Bristol Myers Squibb (NYSE: BMY) presents a compelling investment opportunity despite recent modest revenue growth and upcoming patent expirations. The company has successfully launched new products like Opdualag, Breyanzi, and Camzyos, and has a robust drug pipeline. With a forward-looking P/E ratio significantly below the sector average, it could appeal to long-term dividend investors.

**4. Ascent Group LLC Sells 37,850 Shares of Bristol Myers Squibb Company $BMY**
- Source: MarketBeat | 20260103T080735 | Neutral | Relevance: 100%
- Ascent Group LLC significantly reduced its stake in Bristol Myers Squibb Company (NYSE:BMY) by 70.7%, selling 37,850 shares and retaining 15,656 shares valued at approximately $706,000. This comes as Bristol Myers Squibb reported strong quarterly earnings, beating analyst estimates, and raised its quarterly dividend to $0.63 per share. Other institutional investors showed mixed behaviors, with some increasing and others decreasing their positions in BMY.

**5. BMS provides HCPs with a World of Gratitude in recent ad spot**
- Source: Medical Marketing and Media | 20260105T200805 | Bullish | Relevance: 100%
- Bristol Myers Squibb (BMS), in partnership with Real Chemistry, launched a 30-second ad spot titled "World of Gratitude" as part of its Champions in Care campaign. This initiative encourages people to thank healthcare providers and highlights the dedication of frontline workers, aiming to foster a broader culture of appreciation. The campaign is a response to BMS's research indicating high burnout and undervalued feelings among HCPs, and it will continue to evolve into 2026 and beyond.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | B of A Securiti | $61 | $52 | +17% |
| 2025-12-12 | Morgan Stanley | $37 | $36 | +3% |
| 2025-12-12 | Guggenheim | $62 | $0 | 0% |
| 2025-12-10 | Wells Fargo | $55 | $53 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | B of A Securiti | up | Buy |
| 2025-12-12 | Morgan Stanley | main | Underweight |
| 2025-12-12 | Guggenheim | up | Buy |
| 2025-12-10 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($0.00M) |
| Sells | 2 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 41.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+0.5%)
- Blackrock Inc.: 8.6% (+1.9%)
- JPMORGAN CHASE & CO: 8.5% (+65.8%)
- State Street Corpora: 4.7% (+2.0%)
- Charles Schwab Inves: 3.6% (+3.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 3 raises (avg +8%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 2.26 elevated, pricing in significant growth expectations. Quality metrics strong (ROE 34%). Balance sheet: $6.0B free cash flow. Revenue declining -8% YoY, concerning. Analyst sentiment positive (3 raises, avg +8%). Institutional flow bullish (7 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $108.0B |
| Beta | 0.29 |
| 52W Range | $42.52 - $63.33 |
| Short Interest | 1.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.26 |
| Forward P/E | 8.8 |
| Current P/E | 8.1 |
| YoY Growth | -8.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at -0.9% (minimal 5-day change). Below STRENGTH zone by 3.9pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.09x) but short-term weakness (below SMA20). RSI neutral at 56. OFD pattern: +DLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.91% (CS: 25) | Neutral |
| RSI_14 | 55.8 | Neutral |
| MACD Histogram | -0.30 | Bearish |
| vs SMA20 | 0.996x | Below |
| vs SMA50 | 1.073x | Above |
| vs SMA200 | 1.094x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $53.06
- **Stop Loss:** $50.94 (4.0% risk)
- **Target:** $55.18 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 406
- **Position Value:** $21,542.36
- **Portfolio %:** 21.54%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-05 (Est: $1.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.52 | $1.63 | +7.6% |
| 2025Q2 | $1.10 | $1.46 | +32.6% |
| 2025Q1 | $1.50 | $1.80 | +19.9% |
| 2024Q4 | $1.47 | $1.67 | +13.8% |

---
*RULE-based L3 | 2026-01-07 09:35 | MRS_10*